What is Aphena?
Founded in 2002 and headquartered in Cookeville, Tennessee, Aphena Pharma serves as a critical link in the pharmaceutical, dietary supplement, and animal health marketplaces. The company specializes in comprehensive manufacturing and packaging solutions, providing essential services for biologics and medical devices. By maintaining rigorous quality standards and specialized facilities, Aphena has positioned itself as a vital partner for firms requiring scalable, compliant, and efficient production capabilities. Its market position is defined by its ability to bridge the gap between complex pharmaceutical development and end-user distribution, ensuring that products meet stringent regulatory requirements while maintaining cost-effectiveness for its diverse client base.
How much funding has Aphena raised?
Aphena has raised a total of $22.8M across 8 funding rounds:
Multiple Rounds
$11.9M
Debt
$4.1M
Private Equity
$2.1M
Private Equity
$3.6M
Unspecified
$134K
Debt
$1M
Private Equity (2010): $1.2M, investors not publicly disclosed
Private Equity (2010): $5.8M led by Enhanced Equity Funds
Private Equity (2010): $4.9M supported by Enhanced Equity Funds
Debt (2011): $4.1M featuring Enhanced Equity Funds
Private Equity (2012): $2.1M backed by Enhanced Equity Funds
Private Equity (2013): $3.6M with participation from Enhanced Equity Funds
Unspecified (2014): $134K led by Maryland Department of Business and Economic Development
Debt (2020): $1M supported by PPP
Key Investors in Aphena
Enhanced Equity Funds
A private equity firm specializing in healthcare investments, focusing on organizational development and value creation for smaller companies.
Maryland Department of Business and Economic Development
A state agency dedicated to fostering economic growth and community service delivery through strategic resource allocation and support.
PPP
Public-Private Partnership
What's next for Aphena?
Looking ahead, Aphena is well-positioned to leverage its historical capital injections to further optimize its manufacturing footprint and technological capabilities. The company's trajectory, marked by a blend of private equity support and strategic debt financing, suggests a focus on long-term value creation and operational resilience. As the pharmaceutical industry continues to face supply chain pressures, Aphena's established infrastructure and deep industry expertise provide a competitive moat. Future growth will likely center on expanding its service offerings within the biologics sector and enhancing its digital integration for supply chain transparency, ensuring the firm remains a preferred partner for global healthcare entities seeking reliable, high-capacity production solutions.
See full Aphena company page
